News from the Broad

The Broad Institute is committed to open sharing not only of its scientific data and tools, but also information and news about our progress towards achieving our mission. Below are just a few highlights from the Broad scientific community.
  • Study explores mutation’s paradoxical role in myeoloproliferative neoplasms

    December 20th, 2015

    Myeloproliferative neoplasms (MPNs) are a series of blood disorders that tend to lead to acute myeloid leukemia (AML). The most common genetic mutation in MPNs is called JAK2V617F, an activating mutation in JAK2 kinase. Although JAK2V617F has been associated with increased DNA damage, MPNs are diseases characterized by genomic stability.

    In a recent paper published by Cell Reports, Broad associate member and senior author Ann Mullally, first author Edwin Chen, and colleagues address this paradox by showing that a DNA helicase called RECQL5 suppresses genomic instability in MPNs even as JAK2V617F instigates a state of DNA damage.

  • Harnessing chemical and genomic data to fight cancer

    December 16th, 2015
    Correlations in basal gene expression and cell sensitivity data reveal insights into mechanisms of action for potential cancer drugs
    Read Full Story
  • Broad, MIT scientists overcome key CRISPR-Cas9 genome editing hurdle

    December 1st, 2015
    Broad, MIT team re-engineers Cas9 system to dramatically cut down on editing errors
    Read Full Story
  • A cellular symphony responsible for autoimmune disease

    November 19th, 2015
    Researchers from the Klarman Cell Observatory use single-cell approaches to tease apart immune cell heterogeneity.
    Read Full Story
  • New analytical method helps in building largest cancer cell line sensitivity dataset to date

    October 29th, 2015

    Small-molecule-sensitivity profiling of cancer cell lines (CCLs) has emerged as an approach to illuminate the mechanism of action of compounds and to launch the early stage of the discovery of new precision therapies. In a study in Cancer Discovery, a team of scientists from Broad Institute's Center for the Science of Therapeutics — led by researchers Stuart Schreiber, Paul Clemons, and Alykhan Shamji — presents the largest CCL sensitivity dataset to date, and an exciting new analysis method, termed “annotated cluster multi-dimensional enrichment” (ACME), integrating information from multiple CCLs and small molecules.